What are Relmada Therapeutics, Inc.'s total assets?

Relmada Therapeutics, Inc. (RLMD) holds $235.4M in total assets, up 750.3% year over year.

How much cash does Relmada Therapeutics, Inc. have?

Relmada Therapeutics, Inc. holds $9.8M in cash and equivalents.

Can Relmada Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 18.26 — current assets exceed current liabilities.

Where does Relmada Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Relmada Therapeutics, Inc. RLMD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$9.78M+750%	$3.5M-9.3%	$1.38M-6.7%	$1.35M-35.1%	$1.15M-13.9%
Short-term investments	$224.19M+765%	$89.51M+118%	$12.5M-76.2%	$19.27M-71.8%	$25.91M-68.5%
Total current assets	$235.34M+751%	$93.98M+105%	$14.85M-73.3%	$21.09M-70.3%	$27.66M-67.2%
Intangible assets, net	——	——	——	——	——
Deferred tax assets	——	——	——	——	——
Other non-current assets	$19.5K-11.3%	$19.5K-11.3%	$21.98K0.0%	$21.98K-59.0%	$21.98K-49.0%
Allowance for credit losses	——	——	——	——	——
Construction in progress	——	——	——	——	——
Total assets	$235.36M+750%	$94M+105%	$14.88M-73.3%	$21.12M-70.3%	$27.68M-67.2%
Accounts payable	$5.73M+353%	$1.57M-62.0%	$1.45M-38.0%	$1.36M-67.4%	$1.27M-75.6%
Accrued expenses	$7.16M+80.5%	$4.86M-21.1%	$3.74M-34.9%	$3.77M+5,313%	$3.97M+3,660%
Total current liabilities	$12.89M+146%	$6.43M-37.5%	$5.19M-35.8%	$5.13M-46.2%	$5.23M-57.7%
Total liabilities	$16.63M—	$7.49M—	$5.41M—	$5.17M—	——
Common stock	150M0.0%	150M0.0%	150M0.0%	150M0.0%	150M0.0%
Additional paid-in capital	$935.95M+37.5%	$784.71M+16.0%	$687.83M+2.7%	$684.22M+3.4%	$680.85M+4.0%
Retained earnings	-$717.32M-8.9%	-$698.27M-9.0%	-$678.4M-9.0%	-$668.31M-11.3%	-$658.44M-13.0%
Total stockholders' equity	$218.73M+875%	$86.51M+144%	$9.47M-80.1%	$15.95M-74.1%	$22.44M-68.9%
Total liabilities and stockholders' equity	$235.36M+750%	$94M+105%	$14.88M-73.3%	$21.12M-70.3%	$27.68M-67.2%
Prepaid expenses and other	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$19.5K-11.3%	$11K0.0%	$21.98K0.0%	$21.98K-59.0%	$21.98K-49.0%
Indefinite-Lived Research and Development Assets	——	——	——	——	——
Net Operating Loss Carryforwards	——	——	——	——	——
Other non-current assets	$19.5K-11.3%	$19.5K-11.3%	$21.98K0.0%	$21.98K-59.0%	$21.98K-49.0%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$224.19M+765%	$89.51M+118%	$12.5M-76.2%	$19.27M-71.8%	$25.91M-68.5%
Software and Technology Licenses, Net	$19.5K-11.3%	$19.5K-11.3%	$21.98K0.0%	$21.98K-59.0%	$21.98K-49.0%
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Other Commercial Liabilities	$7.16M+80.5%	$4.86M-21.1%	$3.74M-34.9%	$3.77M-29.6%	$3.97M-44.7%
Accrued Liabilities, Current	$7.16M+80.5%	$4.86M-21.1%	$3.74M-34.9%	$3.77M-29.6%	$3.97M-44.7%
Accrued Vacation Current	$594.9K—	$535.5K—	$532.6K—	$509.8K—	——
Professional Service Fees Payable	$312.9K-0.1%	$220K-39.3%	$215.4K-14.6%	$257K+6.9%	$313.2K+22.2%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	104.9M+3,376%	73.3M+143%	33.2M+10.0%	33.2M+10.0%	3M-90.0%
Common Stock Shares Outstanding	$37.92M—	$20.01M—	——	——	——
Convertible Preferred Stock Authorized Shares	200M—	200M—	200M—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$104.89K+216%	$73.33K+143%	$33.19K+10.0%	$33.19K+10.0%	$33.19K+10.0%
Number of Exercisable Options	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.00—	$0.00—	$0.00—	——	——
Share-Based Payment - Nonvested Awards (Number)	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	——	——	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Share Price	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	——	——	——	——	——
Accrued bonuses	——	——	$1.38M—	$1.04M—	——
Accrued Fees For Issuance Of Common Stockin Dollars Per Share	——	——	——	——	——
Professional service fees	$312.9K—	$220K—	$215.4K—	$257K—	——
Accrued Research And Development Current	$1.82M—	$3.97M—	$1.53M—	$1.89M—	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$150M0.0%	$150M0.0%	$150M0.0%	$150M0.0%	$150M0.0%
Common stock, shares issued (in shares)	$104.89M+3,376%	$73.33M+143%	$33.19M+10.0%	$33.19M+10.0%	$3.02M-90.0%
Common Stock, Shares, Outstanding	$104.89M+216%	$73.33M+143%	$33.19M+10.0%	$33.19M+10.0%	$33.19M+10.0%
Deferred Tax Assets Capitalized Ramp D	——	——	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets Nonqualified Stock Option	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	——	——	——	——	——
Deferred Tax Assets Stock Appreciation Rights	——	——	——	——	——
Temporary differences related to Texas Margin Tax	——	——	——	——	——
Basis differences on investments	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
Operating Loss Carryforwards	——	——	——	——	——
Other accrued liabilities	$76.1K—	$134.4K—	$80.9K—	$79.4K—	——
Preferred Stock, Par or Stated Value Per Share	$0—	$0—	$0—	——	——
Preferred Stock, Shares Authorized	$200M—	$200M—	$200M—	——	——
Prepaid expenses	$1.38M+131%	$977.72K+10.3%	$967.75K-38.9%	$474.63K-11.7%	$596.41K-20.7%
Prepaid Insurance	$248.7K+27.5%	$411.9K+2.2%	$542.3K-11.3%	$68K-20.9%	$195K+44.4%
Prepaid Legal	——	——	——	——	——
Prepaid Research And Development	$866.6K+226%	$496.5K+26.9%	$333.4K-54.3%	$307.1K-12.1%	$265.9K-44.4%
Programming obligations	$3.74M—	$1.06M—	$221.11K—	$32.12K—	——
Regulatory Asset	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$37.92M—	$20.01M—	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercisable	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share price (in dollars per share)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Relmada Therapeutics, Inc.'s total assets?: Relmada Therapeutics, Inc. (RLMD) holds $235.4M in total assets, up 750.3% year over year.
How much cash does Relmada Therapeutics, Inc. have?: Relmada Therapeutics, Inc. holds $9.8M in cash and equivalents.
Can Relmada Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 18.26 — current assets exceed current liabilities.
Where does Relmada Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.